About Research at UPMC Hillman Cancer Center

For more than 30 years, UPMC Hillman Cancer Center has been committed to all aspects of cancer care.

The internationally renowned research at UPMC Hillman Cancer Center (formerly the University of Pittsburgh Cancer Institute) includes a range of disciplines, from cancer prevention and early detection to novel therapeutic discovery, survivorship, and end-of-life care.

As the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in western Pennsylvania, UPMC Hillman Cancer Center is making vast strides in the global effort to reduce the burden of cancer.

At UPMC Hillman Cancer Center, our researchers collaborate with our clinician-scientists to advance the most promising laboratory studies into novel clinical trials, providing patients with early access to new and innovated treatments. We are also dedicated to the education and training of the next generation of cancer researchers and physicians, and the ongoing recruitment of world-renowned scientists.


Advancing our understanding of cancer through scientific discovery


Preparing the next generation of researchers and clinicians

Community Outreach

Community Outreach

Educating the community on cancer prevention, treatment, and survivorship

Clinical Trials

Defining lifesaving approaches to prevent, diagnose, and treat cancer

Patients and Families

Learn about the conditions we treat, available therapies, and the UPMC Hillman Cancer Center difference

Upcoming Events

There are no upcoming events.

Robert Ferris


Director’s Message

Robert L. Ferris, MD, PhD

UPMC Hillman Cancer Center (Hillman) is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and the preeminent institution in western Pennsylvania for providing cancer care; conducting basic, translational, clinical, and population science research; and educating the next generation of cancer researchers and physicians.

At Hillman, we are quickly advancing the latest research discoveries into pioneering therapies that can benefit the more than 110,000 patients seen each year throughout our integrated cancer care delivery network. Read more in our June 2020 Director's message.